Effects of interventions to improve compliance with antipsychotic medication in people suffering from schizophrenia: Results of recent reviews;Compliance-interventionen in der medikamentösen behandlung schizophrenieerkrankter: Befunde aktueller übersichtsarbeiten

Psychiatrische Praxis

Volumn 32, Issue 2, 2005, Pages 62-67

  Puschner, Bernd ^a   Born, Anja ^b   Gießler, Anne ^b   Helm, Hedda ^b   Becker, Thomas ^a   Angermeyer, Matthias C ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFECT; DRUG EFFICACY; HOSPITALIZATION; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOTHERAPY; QUALITY OF LIFE; RELAPSE; RESEARCH; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 15944373476     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828332     Document Type: Review

References (34)

1. Thornley B, Rathbone J, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane review). Chichester, U. K.: John Wiley u. Sons, 2003
2. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane review). Chichester, U. K.: John Wiley u. Sons, 2003
3. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane review). Chichester, U. K.: John Wiley u. Sons, 2003
4. Hornung WP, Franzen U, Lemke R, Wiesemann C, Buchkremer G. Kann Psychoedukation bei chronisch schizophrenen Patienten kurzfristig medikationsbezogene Einstellungen und Verhaltensweisen beeinflussen? Psychiat Prax 1993; 20: 152-154
5. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sacket DL (eds): Compliance in Health Care. Baltimore: John Hopkins Press, 1979: 1-10
6. Stimson GV. Obeying doctors' orders: A view from the other side. Social Science and Medicine 1974; 8: 97-194
7. Holm S. What is wrong with compliance? Journal of Medical Ethics 1993; 19: 108-110
8. Bebbington P. The content and context of compliance. International Clinical Psychopharmacology 1995; 9 (5): 41-50
9. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavia 2002; 105: 164-172
10. Dodds F, Rebair-Brown A, Parsons S. A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication. Clinical Effectiveness in Nursing 2000; 4: 47-53
11. Gray R, Wykes T, Gournay K. From compliance to concordance: A review of the literature on interventions to enhance compliance with antipsychotic medication. Journal of Psychiatric and Mental Health Nursing 2002; 9 (3): 277-284
12. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002; 63 (10): 892-909
13. Fenton WS, Blyler CR, Hummer M. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin 1997; 23 (4): 637-651
14. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. The Lancet 1996; 348: 383-386
15. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavia 2000; 102: 83-86
16. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatrica Scandinavia 1990; 81: 231-235
17. Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988; 39 (9): 963-966
18. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh jr JL, Davis JM, Lewis DA. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152 (6): 856-861
19. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. British Journal of Psychiatry 1985; 146: 469-474
20. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavia 2002; 106 (4): 286-290
21. Kemp R, Hayward P, David A. Compliance therapy manual. London: The Bethlem and Maudsley NHS Trust, 1997
22. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 2002; 59: 1653-1664
23. Kampman O, Lethinen K. Compliance in psychosis. Acta Psychiatrica Scandinavia 1999; 100: 167-175
24. Dolder C, Lacro J, Leckband S, Jeste D. Interventions to improve antipsychotic medication adherence: Review of recent literature. Journal of Clinical Pharmacology 2003; 23 (4): 389-399
25. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: Meta-analysis. British Journal of Psychiatry 2003; 183: 197-206
26. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. British Journal of Psychiatry 1998; 172: 413-419
27. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: Randomised controlled trial. BMJ 1996; 312: 345-349
28. Becker MH. Understanding patient compliance: The contribution of attitudes and other psychosocial factors. In: Cohen SJ (ed): New Directions in patient compliance. Lexington, MA: D. C. Heath and Co, 1979: 1-31
29. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life. International Clinical Psychopharmacology 1995; 10, Suppl 3: 123-132
30. Löffler W, Kilian R, Toumi M, Angermeyer M. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36 (3): 105-112
31. Geddes J. Generating evidence to inform policy and practice: The example of the second generation "atypical" antipsychotics. Schizophrenia Bulletin 2003; 29 (1): 105-114
32. McDonald H, Garg A, Haynes R. Interventions to enhance patient adherence to medication prescriptions. Journal of the American Medical Association 2002; 288 (22): 2867-2879
33. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R et al. Compliance therapy: A randomised controlled trial in schizophrenia. BMJ 2003; 327 (7419): 834-840
34. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 1998; 36: 1138-1161